MiNA Therapeutics
・・・
※SOSEI：MiNA社に対する3,500万英ポンド投資(25.6%株式取得)および同社買収オプション権(全株式取得)を含む投資契約の締結：プラットフォーム技術の補完、戦略M&Aによる成長戦略。(2017/5/3)
・OUTREACHの結果による段階的な条件付対価体系。"OUTREACHフェーズ1／2a臨床試験からの重要臨床データは、2018年中に明らかになる見込です。"
※SOSEI決算説明会：MiNA社買収のオプション権を含む投資契約：そーせいグループのパイプライン開発の加速並びに拡大、目覚ましく拡張した技術プラットフォームを創出。新たな基盤技術獲得の可能性。(2017/5/12)
：直近12-18 ヶ月の見通し：MiNA：パイプラインがPh2b/3臨床試験へと進展。(MTL-CEBPA 進行性肝がん(HCC)を適用としたPh1/2aの臨床データ読み出し：Ph2b/3へと開発が進捗。)
・その他の適用でMTL-CEBPAのPh1/2a臨床試験が開始。・その他のsaRNAターゲットにおける前臨床試験が開始。
※ClinicalTrials: Phase 1/2a, First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH): "Add, 2a Protocol". (2017/5/24 update)
※ClinicalTrials: First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer: Primary Completion: 2017-09→"2018-09" Study Completion: 2017-12→"2018-12". (2017/6/14update)
※SOSEI (English)：Presentation Material as of July 2017: "For Further Growth.", "Potential to have Two Discovery Engines: StaR & SBDD (Heptares), saRNA Therapeutics (MiNA)". (2017/7/5)
・saRNA Technology offers potential for new discovery engine: RNAa represents a platform technology that can rapidly generate a portfolio of programs: "12 months from target selection to development candidate".
※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA. (2017/9/6)
※MiNA Therapeutics: MiNA Research Team at OTS2017. "MTL-CEBPA has Efficacy in a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC." (2017/9/22)
※MiNA Therapeutics: Seeking a Senior Research Scientist to join its Research Team Developing Novel Therapeutics. (2017/10/14 Closed)
※MiNA Therapeutics: Seeking a Research Technician/Laboratory Manager to Join Its Research Team Developing Novel Therapeutics. (2017/10/15 Closed)
※MiNA Therapeutics: MiNA Research Featured as a HOT PAPER by OTS. Best Ones to Highlight Them! "Novel Therapeutic in Clinical Trials for Liver Cancer." (2017/10/23)